deCODE genetics

deCODE genetics was acquired by Amgen (NASDAQ: AMGN) in December 2012 to uncover risk factors and drug targets for dozens of serious diseases. The company had previously gone public inĀ July 2000 (NASDAQ: DCGN).

Headquarters Reykjavik, Iceland